A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2

BACKGROUND: Increased serum interleukin (IL)-33 predicts poor outcomes in patients hospitalised with coronavirus disease 2019 (COVID-19). We examined the efficacy and safety of tozorakimab, a monoclonal antibody that neutralises IL-33, in improving outcomes in ACCORD-2 (EudraCT: 2020-001736-95). MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkinson, Tom, De Soyza, Anthony, Carroll, Miles, Chalmers, James D., Crooks, Michael G., Griffiths, Gareth, Shankar-Hari, Manu, Ho, Ling-Pei, Horsley, Alex, Kell, Chris, Lara, Beatriz, Mishra, Biswa, Moate, Rachel, Page, Clive, Pandya, Hitesh, Raw, Jason, Reid, Fred, Saralaya, Dinesh, Scott, Ian C., Siddiqui, Salman, Ustianowski, Andy, van Zuydam, Natalie, Woodcock, Ashley, Singh, Dave
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588785/
https://www.ncbi.nlm.nih.gov/pubmed/37868151
http://dx.doi.org/10.1183/23120541.00249-2023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588785/
https://www.ncbi.nlm.nih.gov/pubmed/37868151
http://dx.doi.org/10.1183/23120541.00249-2023

Ejemplares similares